Charles River Laboratories | CRL - Net Income

Stock Price
166.79
Daily Change
-4.44 -2.59%
Monthly
4.43%
Yearly
42.20%
Q2 Forecast
166.17

Charles River Laboratories reported $-276.56M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Agilent USD 305M 129M Dec/2025
Align Technology USD 135.76M 79.01M Dec/2025
Bio-Rad Laboratories USD -341.9M 659.7M Sep/2025
Bruker USD 26M 88.4M Dec/2025
Cardinal Health USD 467M 17M Dec/2025
Charles River Laboratories USD -276.56M 330.98M Dec/2025
Cigna USD 1.23B 55.22B Dec/2025
Concord Medical Services Hldg CNY -27.14M 63.85M Jun/2025
CVS Health USD 2.94B 6.92B Dec/2025
Danaher USD 1.03B 168M Mar/2026
Dentsply International USD -146M 281M Dec/2025
Elevance Health USD 1.76B 1.22B Mar/2026
Galapagos EUR 782.15M 984.26M Dec/2025
Humana USD -796M 991M Dec/2025
Illumina USD 334M 184M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
IQVIA Holdings USD 514M 183M Dec/2025
Laboratory Of America USD 164.7M 96.4M Dec/2025
Lonza CHF 426M 119M Jun/2025
McKesson USD 1.19B 76M Dec/2025
Merck EUR 319M 583M Dec/2025
Mettler Toledo International USD 285.76M 68.27M Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Quest Diagnostics USD 251M 6M Mar/2026
Revvity USD 98.36M 51.71M Dec/2025
Thermo Fisher Scientific USD 1.65B 313M Mar/2026
United Therapeutics USD 364.3M 25.6M Dec/2025
UnitedHealth USD 6.28B 6.27B Mar/2026
Veradigm USD -59.82M 74.35M Dec/2022
Waters USD 225.21M 76.29M Dec/2025
West Pharmaceutical Services USD 138.8M 6.7M Mar/2026